<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137839</url>
  </required_header>
  <id_info>
    <org_study_id>04-253</org_study_id>
    <nct_id>NCT00137839</nct_id>
  </id_info>
  <brief_title>Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung</brief_title>
  <official_title>A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pasi A. Janne, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to figure out what effects (good or bad) the investigational
      drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated
      adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will start taking Tarceva daily by mouth on Day 1 and will continue taking this
      medication daily at home, until participation in the study ends.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2004</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>In this study cohort, treatment duration which parallels the maximum observation time was up to 39 months.</time_frame>
    <description>ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or appearance of one or more new target lesions. Stable disease (SD) is neither PR nor PD. For non-target lesions, PD is the appearance of one or more new non-target lesions and/or unequivocal progression of existing non-target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by EGFR Mutation Status</measure>
    <time_frame>In this study cohort, treatment duration which parallels the maximum observation time was up to 39 months.</time_frame>
    <description>ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or appearance of one or more new target lesions. SD is neither PR nor PD. For non-target lesions, PD is the appearance of one or more new non-target lesions and/or unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>In this study cohort, participants were followed for survival up to 155 months.</time_frame>
    <description>OS is defined as the time from study entry to death or date last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival by EGFR Mutation Status</measure>
    <time_frame>In this study cohort, participants were followed for survival up to 155 months.</time_frame>
    <description>OS is defined as the time from study entry to death or date last known alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <arm_group_label>Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Diagnosis of adenocarcinoma of the lung

          -  Patient has had at least one core biopsy of her tumor

          -  Must be willing to undergo epidermal growth factor receptor (EGFR) mutation testing of
             her tumor

          -  Stage four (IV) or three (III) B non-small cell lung cancer

          -  Non-smoker or former smoker. Non-smoker is defined as a person who smoked 100 or less
             cigarettes in her lifetime while a former smoker is defined as a person who has quit
             smoking one or more years ago.

          -  Three or more weeks since last radiation therapy

          -  Three or more weeks since last major surgery

          -  Must at least be able to walk and capable of taking care of herself although unable to
             carry out work activities

          -  Life expectancy of 8 weeks or more

          -  Blood tests that show kidneys, liver and bone marrow to be working adequately

          -  Women of child-bearing potential must agree to use adequate contraception prior to
             study entry and for the entire time enrolled in study

        Exclusion Criteria:

          -  Prior exposure to Tarceva (OSI-774, erlotinib)

          -  Uncontrolled central nervous system problems

          -  Prior chemotherapy regimen

          -  Difficulty swallowing

          -  A disease or disorder that interferes with ability to digest and absorb food

          -  Incomplete healing of previous oncologic or other major surgery

          -  Significant medical history or unstable medical condition such as heart failure,
             active infection, uncontrolled high blood pressure

          -  Pregnant or breast feeding

          -  A medical condition that could make it unsafe for patient to participate in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi A Janne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.dana-farber.org/thoracic-lung-cancer-treatment-center/</url>
    <description>Dana-Farber Cancer Institute Lowe Thoracic Oncology Program</description>
  </link>
  <reference>
    <citation>Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.</citation>
    <PMID>16014882</PMID>
  </reference>
  <reference>
    <citation>Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15;22(16):3238-47.</citation>
    <PMID>15310767</PMID>
  </reference>
  <reference>
    <citation>Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005 May 10;23(14):3227-34. Review.</citation>
    <PMID>15886310</PMID>
  </reference>
  <reference>
    <citation>Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29.</citation>
    <PMID>15118125</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <results_first_submitted>October 8, 2019</results_first_submitted>
  <results_first_submitted_qc>November 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 22, 2019</results_first_posted>
  <last_update_submitted>December 7, 2019</last_update_submitted>
  <last_update_submitted_qc>December 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Pasi A. Janne, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor, Medicine</investigator_title>
  </responsible_party>
  <keyword>Tarceva</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>OSI-774</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Advanced Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled November 2004 to November 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib</title>
          <description>Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Data on Reason Not Completed reflects Reason Off-Study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Start Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prolonged Treatment Delay</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib</title>
          <description>Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>One participant was missing date of birth information.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="34" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EGFR Status</title>
          <description>Mutation status in the epidermal growth factor receptor (EGFR) gene in tumor specimens was determined by standard methods of immunohistochemistry.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Wild Type</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mutant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unevaluable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or appearance of one or more new target lesions. Stable disease (SD) is neither PR nor PD. For non-target lesions, PD is the appearance of one or more new non-target lesions and/or unequivocal progression of existing non-target lesions.</description>
        <time_frame>In this study cohort, treatment duration which parallels the maximum observation time was up to 39 months.</time_frame>
        <population>The analysis dataset is comprised of all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib</title>
            <description>Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or appearance of one or more new target lesions. Stable disease (SD) is neither PR nor PD. For non-target lesions, PD is the appearance of one or more new non-target lesions and/or unequivocal progression of existing non-target lesions.</description>
          <population>The analysis dataset is comprised of all treated participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="18.5" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR) by EGFR Mutation Status</title>
        <description>ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or appearance of one or more new target lesions. SD is neither PR nor PD. For non-target lesions, PD is the appearance of one or more new non-target lesions and/or unequivocal progression of existing non-target lesions.</description>
        <time_frame>In this study cohort, treatment duration which parallels the maximum observation time was up to 39 months.</time_frame>
        <population>The analysis dataset is comprised of all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>EGFR Mutant</title>
            <description>Mutation status of the epidermal growth factor receptor (EGFR) gene in tumor specimens was determined by standard methods of immunohistochemistry.</description>
          </group>
          <group group_id="O2">
            <title>EGFR Wild Type</title>
            <description>Mutation status in the epidermal growth factor receptor (EGFR) gene in tumor specimens was determined by standard methods of immunohistochemistry.</description>
          </group>
          <group group_id="O3">
            <title>Unevaluable EGFR</title>
            <description>Mutation status in the epidermal growth factor receptor (EGFR) gene in tumor specimens was determined by standard methods of immunohistochemistry.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR) by EGFR Mutation Status</title>
          <description>ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or appearance of one or more new target lesions. SD is neither PR nor PD. For non-target lesions, PD is the appearance of one or more new non-target lesions and/or unequivocal progression of existing non-target lesions.</description>
          <population>The analysis dataset is comprised of all treated participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" lower_limit="39.6" upper_limit="72.2"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="12.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as the time from study entry to death or date last known alive.</description>
        <time_frame>In this study cohort, participants were followed for survival up to 155 months.</time_frame>
        <population>The analysis dataset is comprised of all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib</title>
            <description>Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is defined as the time from study entry to death or date last known alive.</description>
          <population>The analysis dataset is comprised of all enrolled participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="15.7" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival by EGFR Mutation Status</title>
        <description>OS is defined as the time from study entry to death or date last known alive.</description>
        <time_frame>In this study cohort, participants were followed for survival up to 155 months.</time_frame>
        <population>The analysis dataset is comprised of all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>EGFR Mutant</title>
            <description>Mutation status of the epidermal growth factor receptor (EGFR) gene in tumor specimens was determined by standard methods of immunohistochemistry.</description>
          </group>
          <group group_id="O2">
            <title>EGFR Wild Type</title>
            <description>Mutation status in the epidermal growth factor receptor (EGFR) gene in tumor specimens was determined by standard methods of immunohistochemistry.</description>
          </group>
          <group group_id="O3">
            <title>Unevaluable EGFR</title>
            <description>Mutation status in the epidermal growth factor receptor (EGFR) gene in tumor specimens was determined by standard methods of immunohistochemistry.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival by EGFR Mutation Status</title>
          <description>OS is defined as the time from study entry to death or date last known alive.</description>
          <population>The analysis dataset is comprised of all treated participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="24.4" upper_limit="44.0"/>
                    <measurement group_id="O2" value="9.9" lower_limit="6.6" upper_limit="16.2"/>
                    <measurement group_id="O3" value="15.7" lower_limit="1.4" upper_limit="109.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) based on the National Cancer Institute's Common Toxicity Criteria for Adverse Events version 3 (CTCAEv3) were assessed every 4 weeks on treatment. In this study cohort, treatment duration which parallels the maximum observation time was up to 39 months.</time_frame>
      <desc>Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. All remaining events regardless of treatment attribution were classified as Other AEs. No further data is available to specify classification of other beyond the general term.The analysis dataset for AEs is comprised of all treated participants versus all enrolled for all cause mortality/any death on study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib</title>
          <description>Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut, eye NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Muco/stomatitis (symptom) pharynx</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hematologic-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>DIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Arrhythmia-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>C-P arrest, non-fatal, cause unknown</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac-other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>External ear, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyopthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vision-blurred</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ocular-other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Eye, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dentures or dental prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anus, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lower GI, hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rectum, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper GI, hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdomen, pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oral cavity, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oral gums, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Constitutional, other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Death - multiorgan failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Death - sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chest/thoracic pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/ gr3-4 neut, wound</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, external ear</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, eye NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, lip/perioral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, lung</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, nerve-periph</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, stomach</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, ungual</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, upper airway</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, vagina</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, wound</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC dental-tooth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC middle ear</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC nose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC oral cavity/gums</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC pharynx</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC ungual (nails)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC vagina</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC wound</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection Gr 0-2 neut, blood</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death - disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Coagulation-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nonneuropathic lower extr muscle weak</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nonneuropathic generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Back, pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bone, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chest wall, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Extremity-limb, pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Joint, pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscle, pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neck, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neuropathy CN VII face-motor / taste</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neurologic-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ocular-other</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Obstruction-urethra</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal/GU-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, pharynx</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) pharynx</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nose, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Throat/pharynx/larynx, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Induration/fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hemorrhage-other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Jackman, MD</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-6049</phone>
      <email>DJACKMAN@PARTNERS.ORG</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

